Development asset linked to Rani Therapeutics Holdings in public FDA and regional records.
pharma · Ulcerative colitis · central nervous system (CNS) lymphomas · RANI
Rani Therapeutics Holdings
Rani Therapeutics Holdings drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
San Jose, USA HQ
2012 Founded
99 Employees
Public company Type
RANI · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Jose, USA
- Founded
- 2012
- Employees
- 99
- Programs
- 7
- Drugs
- 12
- Patents
- 148
Rani Therapeutics Holdings pipeline
Portfolio lens on 12 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Rani Therapeutics Holdings drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Rani Therapeutics Holdings in public FDA and regional records.
-
Development asset linked to Rani Therapeutics Holdings in public FDA and regional records.
-
Development asset linked to Rani Therapeutics Holdings in public FDA and regional records.
-
Development asset linked to Rani Therapeutics Holdings in public FDA and regional records.
-
Development asset linked to Rani Therapeutics Holdings in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
octreotide
Systemic hormonal preparations (H01)Systemic hormonal preparations (H01) compound in Rani Therapeutics Holdings's portfolio. Mechanism: Somatostatin receptor agonist.
- Mechanism
- Somatostatin receptor agonist
-
Development asset linked to Rani Therapeutics Holdings in public FDA and regional records.
-
Development asset linked to Rani Therapeutics Holdings in public FDA and regional records.
-
Development asset linked to Rani Therapeutics Holdings in public FDA and regional records.
-
ustekinumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-12.
- Target
- Interleukin-12
- Mechanism
- Interleukin-23 inhibitor